HIV l-Base (A company limited by guarantee) REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 Charity No: 1081905 Company No: 03962064
HIV l-Base Contents Page Report oflhe trustees Independent examinerfs report Statement of financial activities 10 Balance sheet Cash Flow Statement 12 Notes to the financial statements 15-21
HIV l-Base Report of the trustees Year ended 31 MARCH 2025 REFERENCE AND ADMINISTrAnVE DETAILS Registsred Company number 03962064 Registered Charity number 1081905 Registsred office 2nd Floor. Regis House 45 King William Street London EC4R 9AN Trustees H Mhereza-mitchell W F M Stokes C Decle Independent examiner J Howard FCA A2els Audit Servis Limited 2nd Floor, Regis House 45 King William Street London EC4R 9AN Bankers National We5trnin5ter Bank plc PO Box 83 Tavi%tock House Tavi5tock Square London WC1H 9JA Key management personnel as at 31 March 2025 Simon Collins
HIV14ase Report of the trustees Year ended 31 MARCH 2025 The trustees, who are also directors of the charity for the purpose of the Companies Act 2006, present their report with financial statements of charity for the year end 31 March 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities.. Statement of Recommended Practi applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 leffeclive 1 January 20151. 0ECTIVEs AND ACTIVITIES The objectives of the charty are the protection and preservation of public health and for the relief of sickness by disseminab.ng lo general prath"b"oners and other health care professionals. the resutts of research and other infomiation concerned with the causes, the transmission and the Ireatrnenl of Human ImrnunodeficnCy Virus IHIW, and related conditions so as lo improve the treatment of people living with HIV and prevent the transmission of HIV and related conditions., by providing infomation, advi and other assistan lo those with HIV or related conditions and lo their families and carers and to benefit individuals. both nab"onally and internationally,. through di%seminalion of up-104ate medical and social information related to the treatment and prevention of HIV and other related health issues. A commitment lo the public benefit wthin the obj-eth.ves and activib.es of the organisab.on indudes a belief that.. People INing with HIV who understsnd HIV treatment and prevention are more likely to be adherent lo and benefit from these strategies. People living with HIV on SU$sful Ireaknenl can ad working INes and contribute lo society in many ways. People lThiing with HIV with undetectable viral load on treatment have a zero risk of transmith.ng HIV their partners and almost zero risk of transmitting HIV to their infants lin the case of mothers with HIW - giving enomious benefit to Indivua1S and public heaKh. HIV negative people can also use antiretrowraLs lo redu their risk of becoming HIV positi've- also conferring benefits lo indNiduals and public health. The charity activities to achieve these objectwes indude the followng projects. HIV Treatsnenl BUltin IHTBI, a technical review of the latest medical research aimed al doctors and other healthcare professionals and distributed by email and online. A range of non-technical Ireabmenl guides, wth easy-to-understand infomation for people living with HIV and people at risk of HIV. Distribution is online and in printed format to indNiduals, HIV diniLS and community organisations. These are regularly updated. An Open-aC$S free treatment infomalion Selv by email, post and telephone and online, answering more than 5.000 quesb.ons each year. A website broadening access lo our publications and archives and publirysing our acb"vib"es. Al publications are available online as html pages and PDF fomiaL Working with researcher5 as community representatives and advisors. National and intemational advocacy work induding. policy and technical input to treatment and prevention guidelines, clinical trials and dwg devekjpment. We serve on community advisory boards. guideline writing groups and trial steering committees to ensure that the needs of people living with HIV are represented. Engaging with national and international research groups and guidelines panels. As part of restructuring this year, these projects were completed during the year and are no longer active. Fil for Purpose- a review of the latest research and developments in optimised HIV treatment for low- and middle-income lUntrIeS {LMICsl. Modem ART for South Africa- treatment and research infomiation for adivists from South Africa - including printed materials, app, website, videos and training. A series of small A7 pocket leaflets with less text than the guides. also distributed free to HIV clinics. UK CAB community network to provide education training for people living wth HIV and their advocates. Supporting AfroCAB to develop a similar community network lo UKCAB across several African countries.
HIV l-Base Report of the trustees Year ended 31 MARCH 2025 ACHIEVEMENT AND PERFORNcE Review of a¢tivitigS HIV i-Base is a treatrnent actmst group, led by people living with HIV and committed to providing timely HIV Irealmenl infomiation both lo healthcare professionals and to pople liwng with HIV and their advocates. HIV i-Base was fomed in March 20CH) and has continued to report the most innovatsve and important medical advances in HIVIAIDS. 2025 is our 26th year as a charity- HIV14ase Projects Publications During the period, we continued lo produce HIVTreatsnenl Bulletin {HTBI, and our community publications. HTB is now a news stream rather than a compiled monthly publication. 11 is supported by artS for the most important reports on soryal media platfornis. HTB is distributed to approximately 1600 email subscribers, wilh adeS also distributed in email bulletins to roughly 1000 members of CHIVA and BHIVA. It is also aCsSed direcdy from the i-Base website. Articles are also publicised on soaal media. We continued dislribuling the remaining printed stod(s of the non-technical guides bLrt also made decided to primarily focus on online publishing. Although sexual health clinics still value and want printed resources, these have become increasingly drfficult lo fund. This deasion is also related lo i-Base moved from a physical lo a virtual working offi. One exception is the UK Guide lo PrEP which, thanks to a small grant, wll continue to be printed and distributed fe lo clinics. Although remaining print stocks of treatment guides were distributed until August, demand for publications still continued. We mel this need by dislribubng posters and post-cards with QR codes bul continue lo fundraise for some print reSoUrS including the UK guide to PrEP. This year the PrEP guide was particularly important for reporting planned updates lo the UK PrEP guidelines. A print run of 20.000 of these guides was distributed to UK clinic3 between April and August. From September lo March we distributed 500 A4 posters and 8000 A6 postcards that included QR codes lo this online guide. All the key guides continue to be routinely updated online. Support to clinical research and comrnunty outreach Community involvement in clinical reseah Several stsff continued to be involved as community representstives with several research groups, including on guidelines panels, trial steering committees and advisory boards. This involvement helps bridge the gap between re5earcher5 and the IxmmunitES that their research is hoping to benefit. We help ensure greater aWanesS of Ihe issues that affecl each group and active involvement of other community advocates in these netsvorks. This area has increased in rent years and indudes involvement in a number of important intemab.onal studies. This has also been one ofthe key aims for the UK-CAB. During 2024-25, advocates al i-Base were involved in the DolPHIN 1 and 2 studies, ODYSSEY study, the INSIGHT network, International ADS Society IS) Cure Working Group. Long-AclinglExtended Release Anlirelroviral Research Resour Program ILEAPI, the POPPY study, Public Health England IPHEI, UK-CHIC Database, UK Drug Resislan Database, the RIO Study Icure-related research using bNAbsl. the SIMFT study {with semaglutide) and the Liverpool University Drug 1nleracts.on website. We were also involved in the CADO and PADO {adult and paediatric treatment optimisation groups), the AWG, PAWG ladult and paedialrie ants'retroviral working groups) and HIV pregnancy working groups and of the WHO HIV departmenL
HIV14ase Report of thg trustses Year ended 31 MARCH 2025 ACHIEVEMENT AND PERFORMANCE- continued We infomially supported other research groups advi on parbapant infomialion material and study design. i-Base advocates were also involved as comrnunity representatives or in fomially commenting on national and intemational guidelines panels induding this year the European HIV tymphoma guidelines. i-Base advocates are usualty contn"bvting authors on more than 20 peer-reviewed papers or conference presentstions each year. Meetings. workshops and training UK We continued to run treatment workshops with community groups in the UK induding as part of the UK-CAB programme. The UK£AB i-Base founded the UK-CAB in 2002 and continued to prode administrative support for more than 20 years. This has been a highly Suc$sful project and now connects more than 700 advocates, broadly reffecting the UK demographics. Approximately 40°k of members are women and 40.kn are fr(Kn migrant populations. Part of restructuring pBase this year inVoed finding a new organisalion to provide administrative support for the UK- CAB. We were very lucky lo transfer the UK-CAB lo Positively UK al the end ofAugusl 2025. We were able lo do this with the active support of the UK-CAB chair. sleeriThJ group and wider membership. i-Base are proud of the role we have had to develop and support the UK-CAB for so long and we are very happy and confident that il will continue lo be a vibrant and essential organisation with PosilNe UK. UK-CAB meetings i-Base organised UK-CAB training meetings this year in May and August before the handover. May 2024- UK-CAB meeting after the BHIVA Spring conferen (Bimiinghaml August 2024 - Cognitive impaimient, Viiv Healthcare and IAS 2024 confen feback (London) All presentations and materials from these meetings are online". htt s=Ilukcab.neVmeetin sl ast-meetin s-archivel UK-CAB forurn From April to August 2024, the members forum continued to be a foojs for discussions on a wide range of treatrnenl related topics. The CAB also co-ordinated wider community responses lo the approval pr5$ for new drug approvals and developing topics for the community sessions at the BHIVA conference. Forum discussions covered all aspects of HIV care including treatsnenl updates and questions, HIV cure research including the RIO and other studies, conferen, webinars and other HIV online training annoUnments and changes in the CAB structure and the handover to Positive UK. UK-CAB and community repwesentation UK-CAB provides a unique collective community Vol and broad range of lived expertise from many different communities. We have a consliluent network lo represent and report lo. We ensure transparency with the wider community and over the years many dodors, researchers and policy makers actively seek community views from the UK-CAB. Members have also been on several writing groups and tsken a lead role in the production of the non-tethnical summaries for these guidelines. We also mentor several new wrib.ng group representstives. Infomation on this programme". htt '.lth.ukcab.neUabouVcommuni -re resentativesl
HIV14ase Report of thg trustses Year ended 31 MARCH 2025 ACHIEVEMENT AND PERFORMANCE- continued Full list of UK-CAB community representalwes". htt s=Ilukcab.neVcommunit -re resentationlcommuni -re resentativesl UK-CAB collaborations UK-CAB works with professional bodies. These indude.. British HIV Associab"on IBHIVAI. National HIV Nurses As50cialion {NHIVNAI. A wide range of NHS HIV dinics. NICE (National Institute for Health & Care EXllencE). Medical Research Council Clinical Trials Unit Medicines and Healthcare products Health Regulatory Agency. Various dinical trial steering CL)mmittees with National Institute of HIV Research. universities and other b¢xJies. International training and transition to African oryanisations After more than a decade of dose collaborations, i-Base wound down involvement in a major project that developed and updated community matenals in the Modern ART for Africa series. This projed supported the introduth.on of optimised antiretroviral treatment in low- and middle-income countrie5. It induded print, website and other resou$ that continued lo be developed and updated. htt s'.IlmodernartForsouthafrica.co.za During 2024, as part of the long-term goal to transition thi5 project to organisation5 based in South Africa, the Modern ART project was passed lo Ezintsha who will continue to develop this wolk in partnership with the Treatment Action Campaign Website and Q&A services The i-Base website continued to generate hvJh levels of use with approximately 200.000 to 300.000 web visits each month, roughly indivKlual 3 million hits over the year. These figures vary a5 the algorithms used by search engines induding Google are contsnually being updated. The website continues to be assessed by people from more than 100 countries and territories globally. The countries with highest use were South Africa125%1. India {17%1, USA {12%1, UK {10%) and Nigeria, Kenya and Uganda leach with 7-8Yol. From April 2024 to March 2025, the Q&A Servi responded lo 7479 questions, with roughty 4960 email requests and 2519 online comments. This was roughly a 10% increase on the previous year and this is the third consecutive year that demand has increased. All infomation is monitored and logged anonymously and the regional distribution for the service remains similar to previous years.. approximately 1 OQkn are from the UK and 90Qh are inlemalional. The distribution of issues remains similar roughty haw the enquiries linked to HIV prevention with 30¥0 covering lesling and transmission and 17% on PEP and PrEP. Alhough our primary focus is on treatment and care for people living with HIV, the increasing use of the same dwgs for HIV prevention means thatwe also respond to these questions.
HIV14ase Report of thg trustses Year ended 31 MARCH 2025 ACHIEVEMENT AND PERFORMANCE- continued The main treatment-related issues raised in emails. each accounted for about 4 10 70k of enquiries. Pregnancy, breast feeding and infant prophylaxis Treatment induding a¢$5 and starting treatment Adheren and resistance Drug interactions CD4 count, viral load and U=U New diagnosis, symptoms and healthy lifestyle Side effects Disdosure and serodifferenl couples This service is supported by grants from Gilead SCiens and Viiv Healthcare. Websitel All i-Base publications continue lo be published on the website and our online Q&A answered several thousand of questions and online comments thts year. The website was accessed by around 3 million people from 6.5 million hits. The sile has been accessed by people from 230 of the world's 241 countries and territories. It was designed and updated lo have fast access even wlh dial-up or unreliable aC$S lo the Inlemel, induding on mobile phones and tablets. The website is continually updated to be match guhlelines for access on handheld dewces. FINANCIAL REVIEW i-Base has a policy of maintaining unrestricted funds, which are the free reserves of the charity, al a level, which equates lo approximately thMonthS lotsl expenditure. At the year end the free reseNes exeded this. During the first half of the financial year, we worked on re5truclured i-Base to run on a minimal budget. This included changes in staffing, income and running costs. For roughty the first six months, i-Base continued some existing services while winding down and handing over others. Many stsff wanted lo erther retire or focus on other activities and we wort(ed with an independent CCsu1tant to support transib"oning lo other organisalions or arranging planned managed redundancies. For the second six months, i-Base moved to a minimal emergency budget in order lo estsblish a more Secu long- term basis for the organisation. This induded giving up the rented offi. reducing print resources and moving lo volunteer rather than paid staff. Thi5 was a150 in response to the restn"ctions funding support similar lo many other organisalions in the HIV sector. As a result. i-Base has continued many of the projects above on a much redUd budget but a150 established a model that should sustain web-based servIS for al least the next two years. The Trustees are pleased to report that during the year to 31 March 2025 i-Base succtssfully transitioned the African support projects and the UK-CAB lo new organisats"ons. This induded transferring any ring-fend funding for the remainder of any grant period. The direct infomalion serVIS lexduding publItIonS) and the educational meetings for the UK-CAB were supported by several grants from pham1aUtica1 companies totalling £24.183 from Gilead sryens and Viiv Healthca. This support i% aayS independent of editorial content and programming which remains separate from these awards. Unreslricled funding for core costs remains difficutt to secure and has been one of the main risks lo the charity in cent years. For example, i-Base hasn't received ststulory funding
HIV14ase Report of thg trustses Year ended 31 MARCH 2025 FINANCIAL REVIEW- continued for many years and is unlikety to do so in the near future. However, cuts in NHS and Public Health England funding means less support for peop living with HIV and related infections from soaal servi. This is reflected in an HIV I- Base increase demand for our infomiation services and publications. i-Base aL%o tends to quickty respond to the need for new reSoUrs, irrespects've of whether these are speafically funded. This induded COlVtk19 and mpox in re(Ent years and this year il inVoed responding to dramatic changes in the US policy on international aid, including PEPFAR, Sin 20 January 2025. This led to i-Base being active in several intemalional neorts, including providing infomiation lo more safely manage the difficults.es of closed sexual health clinic and uncertain access to ART. We worked dosely wth WHO for online infr)rnialion and webinars and worked with researcher5 on future management options including the potential for less than daily dosing. Support from pharmaceub.cal companies is dependent on the priorities and governan of the individual companies and we are lucky that two of the leading companies value and support our wowk. These funding i%sues have aayS been the case and over the last 20 years there has been suffiaent flexibility for some level of support to contribute towards oijr work. Most notabty. the number of companies In the field and their community budgets have both decreased. We still continue to apply for fvnding from a wider range of sources whenever this is in line with our objectives. Total income for this year wa5 £67,757 compared to £315,715 in the previous year. Nel reSoUrS expended for the year amounted to £299.973 compared to £ 496,183 in the previous year. Year end results show a deficit of £232,216. FUTURE PLANS i-Base was founded in 2000 to fill a gap that wasn't being mel by exists'ng Htv servi5 and organisation in the UK. sin then. we have continued lo focus on projects related to the evofving Scien being HIV treatment from an activist and peer-led perspective. We still focus on providing specialised treatment infomialion that makes us an internationalty recognised and trusted community organisalion. We have never been interested in duplicab.ng anything that is already being prOdUd. Even running on a redUd budget. our semces and perspeth'ves are unique and enable us to effectively support and Influen the work of others. Although based in the UK i-Base has always actively linked with sirnilar HIV organisations in other countries and gions. We hoped that restructuring i-Base and moving to an emergency budget wll enable the project to continue into the future.
HIV l-Base Report of the trustees Year ended 31 MARCH 2025 STRUCTURE. GOVERNANCE AND MANAGEMENT ststus HIV i-Base is a eharilable company limited by guarantee. incorporated on 28 March 2000 and registered as 8 charity on 8 August 2000. The financial statements compty current statutory requirements, the Memorandum and Arti&s of Association and the Statement of Recommended PractI- Accountsng and Reporting by Chanties. Trustsgs A new Trustee, Mr Christian Decle, was recruited in May 2024. The boa1 of Trustees are listed on page 1. Trustees have a personal conneth.on and interest in i-Base's work as well as some experience of charity govemance. An induction pack is provided for new Trustees, and they are invited to meetings and events organised by the organisation and to develop involvement in all our woth. Management i-Base has a policy that reviews salaries on an annual basis following annual stsff reviews. Although staffing is now redUd the organisation will link any future salaries to NJC salary scales Risk Management As part of the annual planning process, the trustees identify the major risks {ffinancial, operational, governanlCoMplIanee and exlemal risks) facing the Charity over the coming year. Each risk is assessed according to the likelihood. and polenkn.al impact and systems and procedures are agreed to manage those risks which are implemented by the trustees and staff. Some of the main risks facing the charity are detsiled below arKI how these risks are being contained.. Fundraising for unreslricled fijnds. Mib"gation indudes a focus on developing new income streams and relationships and dose monitoring of income and expenditure. Moving lo a redUd budget means that the remaining risks in this category are assessed as medium. This is in spite of redUd funding opportunities. Moving to a virtual Offi Spa from 1 September 2024 signfficantly redutxl running costs. Approved byorderof the board of trustees on.................................................. and signed on its behalfby". W F M Stokes
HIV l-Base Independent examine5 report Year ended 31 MARCH 2025 l pOrt lo the charity Iruslees on my examination of the accounts of the charity for the year ended 31 March 2025, which are sel out in the attached Slatemenl of Finanaal Actsvitses. the Balance Sheet and the related notes. Responsibilities and basis of report As the trustees of the charitable company (and also its direclors for the purposes of company lawl, you are responsible for the preparation of the finanryal statements in accordan the requirements of the Companies Act 2006. Having satisfied mysew that the financaal ststements of the tharitsble company are not required lo be audited under Part 16 of the Companies Act 20 and are eligible for independent examination. I report In respect of my examination of the charitable company s finanaal statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145{5){bl of the Charities Act 2011. Independent eXarnineS staternent I have completed my examination. I confimi that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect.. accounts'ng records WEre not kept in respect of the thantsble company as required by section 386 of the Companies Act 2006. the financial statements do not accord those records., or the financial slalemenls do not comply with the accountsng requirements of section 396 of the Companies Act 2006 other than any requirement that the financial ststements give a true and fair view, which is not a matter considered as part of an independent examinab"on', or the financial statements have not been prepared in accordance the methods and prinaples of the Statement of Recommended Practice for accounting and reporting by charib'es applicable lo charities preparing their finanaal slalemenls in accordance with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland (FRS 1021. I have no conMS and have come across no other rnatte in connection with the examination to which attention should be drawn in this report in order to enable a prorer understsnding of the accounts to be reached. J HovArd FCA Azets AuditSer4ices nd 2 Floor, Regis House, 45 King William Street London, EC4R 9AN Dale
HIV l-Base Statement of financial activities (incorporating an income and expenditure account) Year ended 31 MARCH 2025 Notes Unrestricted Funds Restricted Funds Total 2025 Total 2024 Income: Donations and legac5 Investsnenl income 9,934 2,196 55,627 65,561 2,196 310,719 4,996 Total income 12.130 55,627 67,757 315,715 Expenditure: Raising funds 4,909 4,909 28,306 Charitable aclivilie5 209,158 85,906 295,( 467,877 Total resources expended 214.067 85,906 299,973 496,183 Net incomgllexpenditure) before transfers {201,9371 130,2791 {232,9731 {180,4681 Transfers beeen funds Net movement in funds (201.937) 130.2791 {232,9731 {180.468) Fund balanS brought forward 306,697 30,771 337,468 517,936 Fund balances carried foThvard at 31 MARCH 2025 12 104.760 492 105,252 337.468 The notes on pages 13 to 21 fomi part of these financial statements. 10
HIV l-Base Balance Sheet As at 31 MARCH 2025 2025 2024 Notes Fixed assets Tangible fixed assets 2.451 4,089 Current assets Debtors Cash al bank and in hand 10 11,436 110,072 26,970 358,426 121.508 385,396 Creditors: Amounts falling due wthin one year 11 (18,707) 152,0171 Net current assets 105,801 333,379 Net assets 105.252 337.468 Funds Reslricled funds Unrestricted funds 492 104,760 30,771 306,697 13 105,252 337.468 The company is enb.lled to exemptson from audit under seth.on 477 of the Compan$ Act 2006 for the year ended 31 March 2025. The members have not required the company to obtsin an audit of its finanryal statements for the year ended 31 March 2025 in accordan with sedion 476 of the Companies Act 20(k5. The directors ad(nowledge their responsibilities for.. al Ensuring thatthe company keeps aco)unting records which o)mptywith section 386 and 387 ofthe companies Act 2006 and bl Preparing financial statements which gNe a true and fair view of the stslemenl of affairs of the company as al the end of each financial year and of its surplus or defiut for each finanaal year in accordan with the requirements of sections 394 and 395 and which otheiSe comply the requirements of the Companies Act 2006 relating to financial statements. so far a5 applicable to the company. The financial statements have teen prepared in cordan with the specaal provisions of Part 15 of Companies Act 2006 relab.ng to small companies. Approved by the Board on and signed on their behalf by". W F M Stokes The notes on pages 13 to 21 fomi part of these financial statements
HIV l-Base ststement of Cash Flows As at 31 MARCH 2025 2025 2024 Note Cash flow from operating activities 17 1250,550} 1168,7761 Net eash flow from operating activities {250,550} 1168,7761 Cash flow from investing activities Payments to acquire tsngible fixed assets Interest reiVed 13,6681 4,99S 2,196 Net cash flow from investing activities 2,196 1,328 Net increase I Ideerease) in cash and cash equivalents Cash and cash equivalents atthe beginning of the reporting period {248,354} 358.426 1167,4481 525,874 Cash and cash equivalents at the end of the reporting period 110,072 358,426 Cash and cash equivalents consists of: Cash at bank and in hand 110,072 358,426 Cash and cash equivalents at end dats 2025 110,072 358,426 The notes on pages 13 to 21 fomi part of these ffinancial statements 12
HIV l-Base Notes to the financial statements Forthe year ended 31 MARCH 2025 Accounting policies General infomiation and basis of preparation HIV l-Base is a company limited by guarantee in the United Kingdom The liability of each member in the event of winding-up is limited lo £10. The address of the registered Offi is given in the charity information on page 8 of these financial stslements. The nature of the charity's operab.ons and prinupal activities are set out on page 1. The tharitable company constitutes a public tenefft entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities.. Statement of Recommended Practi applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 issued on 16 July 2014, the Financial Reporting Standard applicable in the United lQ"ngdom and Republic of Ireland IFRS 1021, the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Practice a5 It applies from 1 January 2015. The finanryal statements are prepared on a going nCeM basis under the historical cost convenb"on. modified lo indude rtain items at fair value. The finanal statements are prepared in sterling which is the functional currency of the charity. The significant accounting polioes applied in the preparats.on of these finanual statements are sel out below. These poliaes have been consi5tenUy applied to all year5 presented unless otherwise staled. b} Going Concem The financial statements have been prepared on a going conrn basis as the trustees believe that no material UnrtaIntieS exist. The trustees have considered the level of fvnds held and the expected level of income and expenditure for 12 months from authorising these finanoal statements. The budgeted income and expenditure is sufficient with the level of reserves ft)r the charity to be able to conts.nue as a going concern. Fund accounting Funds held by the tharity are either.. Unrestricted general funds- these are funds which can be used in accordance with the charitable objects at the discretion of the trustees. Restricted funds- these are funds that can onty be used for particular restricted purposes within the objects of the charity. Reslriclions arise when specffied by the donor or when funds are raised for the particular reslricled purposes. Further explanath?n of the nature and purpose of each fund is included in the notes to the finanaal statements. 13
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 Accounting policies- continued d} Income All incoming resources are including in the Statement of Financial Activib"es ISOFAI when the charity is legally enlided to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that income will be r1ved. Donation income induding grants.. are recognised in full in the Ststemenl of Finanaal Aclivf(ies in the year in which they are recewable. Such in(x)me is only deferred when the donor specifies that the grant must only be used in future accountsng periods. Grants reiVed for speaffic purposes are treated as reslricled funds. Investment income is included en receivable. Resources expended All expenditure is accounted for on an acuuals basis and has been classified under heading that aggregate all costs related to the catory. Expenditure is recognised where these is a legal or constructive obligation to make payments lo third parbes, it is probable that the settlement wll be required and the amount of the obligation can be measured reliably. The irrecoverable element of VAT ts induded with the item of expenses lo which it relates. 11 is calegorised under the following headings.. Costs of raising funds are those costs incurred in attracting grants and donation income. Charitable expenditure comprise of those costs incurred by the charty in the delivery of ils activities and services for its benefiaaries. It indudes both costs allocated direclly to suth activities and those costs of an indirect nature neSary to support them. Stsff costs are allo(3ted betsveen costs headings according to the fvncb.on of each employee. Support costs allocation Support costs are those Ihal assist the work of the charity but do not direcuy represent charitable activities and indude governance cxists. administrative office funth.on costs. depreryation and premises costs. They are incurred directly in support of expenditure on the objects of the charitable company. Governance costs comprise all $ts involviThJ the public aUnbility of the charity and indude statutory independent examination fees. Support and Govemance costs have been allocated across the charitsble actimties using various perntsge allocations. gl Tangible fixed assets Tangible fixed assets are staled at cost less accumulated depreaation Depreciation is provided on all tangible fixed assets, at rates calculated lo write off the cost of each asset over their esb'mated useful lives 85 follo-. 01 equipment 40% reducing balan basis Individual fixed assets costing £200 or more are c2pitslised al cost. h} Debtors Grants repayable and other debtors are recognised at the setuemenl amount due. Prepayments are valued at the amount prepaid. 14
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 Accounting policies- continued Cash at bank and in hand Cash al bank and sh in hand includes cash and short term highly liquid inveslments with a short maturity of three months or less from date of acquisitions or opening of the deposit or similar account. Creditors Creditors are recognised when there is a present obligat.on resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. other creditors and accruals are recognised at their settlement amount due. kl Financial instruments The charity only has assets and finanaal liabilities of a kind that qualify as basis financial instruments. Basic financial instruments are initially recognised at transaction value and subsequenly measured al their settlement value with the exptIOn of bank loans which are subsequently measured at amorti5ed cost using the effective interest method. Operating lea$e$ Rentals payable under operating lease5 are charged to the Statement of Finanal Activities as incurred over the temi of the lease Forgign currency Assets and liabilities in foreign currencie5 are translated into sterling at the rates of exchange ruling al the balance sheet dale. Transacb"ons in foreign currenoes are translated into stet1ing al the rate ruling on the date of the transaction. Al exchange differences are reflected in the Statement of Financial ActThiities. Tax The charitable company is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definits.on of a charitsble company for UK corporation tax purposes. Accordingly, the charty is potenlialty exempt from tsxalion in respect of income or capitsl gains r1Ved within categories covered by Chapter 3 Part11 Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent thal such income or gains are applied exdusNety to charitable purposes. Pensions The charity contributes to a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the Charity in independendy administered funds. The pension cost charge represents contributions payable by the Charity to the scheme. 15
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 pl Judgements and key sources of estimation uncertainty Accounting eslimales and judgements are continually evaluated and are based on historical expern and other factors. induding expectab.ons of ftjture events that are belEved to be reasonable under the circumStans. The following judgements lapart from those involving eslimatesl have been made in the prOsS of applying the above accounting wlicies that have had the most sgnificant effect on amounts recognised in the finanryal statements.. Useful economic lives of tangible assets The annual depreryation charge for tsngIb assets is sensitive to changes in the esb"mated useful economic lives and residual values of the assets. The useful economic lives and residual values are fE-assessed annually. They are amended when necessary to rellect current eslimales, based on technological adVanMent, future invesknents, economic ulilisation and the physical condits.on of the assets. See note 9 for the carrying amount of the propety. plant and equipmenL and note g for the usefvl economic lives for each class of assets. There are no key assumptions conceming the future and other key Sou$ of estimation unrtainlY al the reporting dale that have a significant risk of causing a material adjustment lo the carrying amounts of assets and liabilities within the next ffinanaal year. Donations and legacies Unrestricted 2025 Restricted 2025 Totsl 2025 Total 2024 Individual, charitable, corporate and intemational donations. 9.934 55,627 65.561 310,719 9.934 55,627 65.561 310,719 In 2024, £155,832 of the donations and legaae5 income was attributable to the restricted lunds, and the maining £154,887 was attributab lo the Un$trled funds. Investment incon Unrestricted 2025 Restricted 2025 Total 2025 Totsl 2024 Bank interest 2,196 2.196 4,996 2.196 2,196 4,996 In 2024, all £4,996 of the investment income was attribU1ab to the unrestricted funds. Raising funds Unrestricted 2025 Restricted 2025 Totsl 2025 Totsl 2024 Cost of generats'ng voluntary income 4,9 4,909 28,306 4.909 4,909 28,306 In 2024, 811 £28,3[ of the CL)St of raising funds was attributable to the unreStrj funds. 16
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 Charitable activities Unrestrieted 2025 Restricted 2025 Total 2025 Total 2024 Information services 121,516 8,863 77,010 130,5T9 77.010 87,441 33 184,917 35,688 247,107 165 UKCAB Research and community development AFROCAB Rainwater 87,441 209,157 85,9C 295.063 467,877 In 2024, £166,302 of the expenditure in relation to charitable acbvities was attributable to the restricted fund, with the remaining £301,575 being attribUtsb to the unrestricted fund. Analysis of expenditure Direct Costs Support Costs (note 6.1 } Total 2025 Total 2024 Cos15 of generating voluntary income Information services 4,909 108,969 45,802 85.711 4,909 130,5T9 77.010 87,441 33 28,306 184,917 35,688 247.107 165 21,610 31,208 1.730 33 UKCAB Research and community development AFROCAB Rainwater 54.581 245.391 299,972 496.183 In 2024, £430,448 of expenditure was attribulable to direct costs, wrf(h the remaining £65,735 being attributable to support costs. Support costs Totsl 2025 Totsl 2024 Bank charges Communications Computer costs Consultancy Depreciab"on Postage, stationery and sundries Rent, rates and insuran staff costs Subscriptions Travel, Subsisten & conference attendan Govemance eosts: Accountancy costs Independent examination Auditors remuneration 365 606 2,455 10,878 1.638 8,702 17,622 196,336 96 13 497 1,925 2,808 210 2,727 2,953 37,854 1,652 96 250 3.430 3,250 7,203 7,560 245,391 65,735 17
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 Staff costs and remuneration 2025 2024 Gross wages and salaries Employerfs national insurance costs Pension Contributions 124,883 8,991 3.511 218,896 17,676 8,799 137,385 245,371 Number Number The average number of employees during the year Calculated on a full time equivalent basi5, wa5.. One employee received remuneration arnounting to more than £60,000 in the year (2024.. two). Trustees received no remuneratson and were not reimbursed for any of their expenses in the year. As of 31 March 2025, the key management of the charitable company comprise one of the co-founders. The total employee benefits of the key management personnel of the charitsble tMpanY were £122,068 12024.. £202,469). Net incomingl{outgoingl resources for the year 2025 2024 This is staled after charging.. Depreaation Auditors, remuneration- audit servi5 Auditors, remuneration- non audit services Independent examination Operating lease rentals- property 1,638 2,727 7,560 1,926 3.250 11,750 23,500 18
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 Tangible fixed assets OlCe equipment Cost Al 1 April 2024 Additions Disposal 36.609 At 31 MARCH 2025 36.609 Depreciation Al 1 April 2024 Charge for the year Disposal 35.520 1,638 At 31 MARCH 2025 34,158 Net book value At 31 MARCH 2025 2.451 At 31 March 2024 4,089 10. Debtors 2025 2024 Grants repayable Prepayments and accrued income Other debtors 2.500 8,145 791 15,818 10,420 732 11.436 26,970 11. Creditors: amounts falling due wtlhin one year 2025 2024 Amounts payable Taxation and social security other creditors Accruals and deferred income {note 11.1) 9,163 6,204 3,177 33,473 18.707 18.707 52,017 12. Analysis of net assets between fvnds Unrestricted funds Restricted funds Total funds Tangible fixed assets Current assets Current liabilities 2,451 121,016 118.707) 2,451 121,508 118,7071 492 104.760 492 105.252 19
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 13. Statement of funds 1 April 2024 Ineoming resources Resources expended Trnnsfer 31 MARCH 2025 Restricted funds AFROCAB UKCAB Information services Research & community development Unrestricted funds General 33 30.271 467 {33} 177.010} 18,8631 46.739 8,888 492 306,697 12,130 1214,067) 104,760 Total Funds 337.468 67.757 (299.973) 105.252 AFROCAB: Funds held on behalf of Afrocab relate lo grants made to Afrocab by various donors lo enable them lo establish a nelwork of HIV positive people and advocates across Su&Saharan Africa based loosely on the UKCAB network established in the UK by HIV l-Base. The group organises meetings on HIV treatment, access to treatment and other topics as well as working with intemalional organisations such as the WHO to canvas opinions from HIV positive people and advocates. UKCAB: Restricted funds relating to the UKCAB are those donated by a number of donors for the specrfic purpose of covering attendance costs at UKCAB meetings for those delegates from outside London. These include travel, accommodation and other expenses such as childcare costs. Research & community development: Restricted funds relating lo Community Outreach Overseas are those granted by WITS RH and HIV Institute for the specific purpose of covering costs relating lo public3b.ons such as print and desvJn costs, travel to meetings, accomm¢Jdation and other expenses such as ground tran5porL 20
HIV l-Base Notes to the financial ststements Forthe year ended 31 MARCH 2025 13.1 Statement of funds- Prioryear 1 April 2022 Ineoming resources Resources expended Transfer 31 March 2024 Restricted funds AFROCAB UKCAB Infomialion servi$ Research & community development 33 40,741 467 33 30,271 467 25.218 44.535 86,079 135.688} 144.535) 186,0791 Unrestricted funds General 476,695 159,883 1329,8811 306,697 Totsl Funds 517.936 315.715 (496.183) 337.468 14. Operating lease ¢ommitn*nts 2025 2024 The minimum annual rentals under operating leases are as follow5.. Within one year Beeen one and five years 13,583 13,583 15. Related party disclosure There were no related paty transaction for the current year or the prior years. 16. Ultimate controlling party The charitable company is considered to have no ullimale controlling party- 17. Re¢on¢iliation of net incom91lexpenditure) to net cash flow from operating activities 2025 2024 Nel incomellexpenditurel for year Interest receivable Depreciation of tsngible fixed assets Disposal of tangible fixed assets Ilncreasel I decrease in debtors Increase I Idecreasel in creditors 1232,2161 {2,19S) 1,638 1180,4681 14,9961 2,727 51 118,4681 32,378 15.534 133,310} 1250,550} 1168,7761 21